Background WHO's 2013 revisions to its Consolidated Guidelines on antiretroviral drugs recommend routine viral load monitoring, rather than clinical or immunological monitoring, as the preferred monitoring approach on the basis of clinical evidence. However, HIV programmes in resource-limited settings require guidance on the most costeff ective use of resources in view of other competing priorities such as expansion of antiretroviral therapy coverage. We assessed the cost-eff ectiveness of alternative patient monitoring strategies.
Introduction
The monitoring of patients on antiretroviral therapy is an important part of HIV care: it determines whether treatment is successful, or if a diff erent drug regimen or improved adherence is required. Patients with treatment failure are more likely to have progressive disease and are at greater risk of dying, and patients with nonsuppressed virus are also at risk of developing resistance and transmitting HIV infections to others. Patients can be monitored and treatment failure can be defi ned in many ways, in terms of the assays used (clinical monitoring with or without the measurement of CD4 count or plasma viral load), the frequency of checks (eg, every 3, 6, 12, or 36 months), and the decision rules applied for change of antiretroviral therapy based on clinical, CD4 count, or viral load criteria.
Every monitoring strategy carries diff erent costs and health consequences. Determination of the cost eff ectiveness of a given strategy requires decision makers to balance the gains in health it provides against the gains in health that could be achieved by allocating resources to other interventions. Health-economic analyses such as those presented here can provide guidance on how to measure and value health outcomes, and on how to allocate scarce resources to generate health gains at the population level.
Since 2006, WHO antiretroviral therapy guidelines have recommended a "public health approach" to antiretroviral therapy scale-up, 1,2 based on standardised and simplifi ed treatment and monitoring. This approach includes a common fi rst-line regimen of a nonnucleoside reverse transcriptase (NNRT) inhibitor plus two nucleoside reverse transcriptase (NRT) inhibitors, of which one should be either zidovudine or tenofovir, that can be delivered in decentralised settings. The 2010 guidelines recommended that patients receive regular clinical and immunological monitoring and, if feasible, virological monitoring and then switch to a diff erent drug regimen (a second-line) once treatment failure is detected using any one of the following criteria:
(1) clinical failure-ie, a new or recurrent WHO stage 4 event; (2) immunological failure-ie, a fall of CD4 count to baseline (the start of treatment) or below, a 50% fall from an on-treatment peak value, or persistent CD4 levels below 100 cells per μL; and (3) virological failure-ie, plasma viral load higher than 5000 copies per mL while on treatment. These three defi nitions can be detected with clinical monitoring, measurement of CD4 cell counts, and viral load monitoring, respectively.
The 2013 WHO Consolidated ARV Guidelines 3 no longer recommend the use of a 50% fall from ontreatment peak value for assessing immunological failure, and recommend viral load monitoring as the preferred approach to diagnose and confi rm antiretroviral treatment failure in both adults and children, with failure defi ned as two consecutive plasma viral loads above 1000 copies per mL within three months of one another after six or more months on treatment. However, countries still need to decide whether programmes currently using clinical or CD4 monitoring should invest resources in upgrading clinics and laboratory infrastructure to use viral load monitoring.
Mathematical modelling and health economic evaluation allows for systematic, detailed consideration of the costs and health consequences of a broad repertoire of potential monitoring strategies over a range of timescales, and can therefore help inform countries' decisions on how to invest limited resources. Consequently, we collated evidence from published modelling studies and undertook new analyses on the cost eff ectiveness of alternative patient monitoring strategies. This study, which informed the WHO Guidelines, aims to identify appropriate monitoring strategies for programmes given their competing priorities and the wide variety of situations and resource constraints that they face.
Methods

Search criteria
To identify modelling groups for the WHO Guidelines process, we identifi ed relevant modelling studies published between Sept 15, 2007, and Sept 15, 2012 , through a search of PubMed/Medline and Google Scholar with search terms including "viral load monitoring", "patient monitoring", "cost-eff ectiveness", "mathematical modelling", "antiretroviral therapy", "modelling patient monitoring", and "HIV treatment monitoring". A list of studies reviewed (including some before Sept 15, 2007 ) is included in the appendix. We included models in the review if they assessed the eff ect of patient monitoring strategies on health outcomes (treatment failure, viral loads, CD4 cell counts, clinical events or progression to AIDS) in a simulated population over time and also incorporated a cost-eff ectiveness analysis. We contacted groups with publications meeting these criteria in the previous 5 years to participate in the WHO Guidelines process.
Models
Given the importance and complexity of the question, it was important not to base fi ndings on a single mathematical model but rather to assemble a set of independently constructed and validated models. We contacted six modelling groups; three agreed to undertake new analyses for the project, 4-8 whereas two 9, 10 did not undertake new analyses but did contribute to the collective analysis presented here. The mathematical models used were: the HIV Synthesis model (Phillips and colleagues, 4,5 University College London, London, UK), Estill and colleagues 6, 7 (University of Bern, Bern, Switzerland), and Braithwaite and colleagues 8, 11 (New York University, NY, USA). The Synthesis and Estill models are parameterised for a generic southern Africa setting, whereas the Braithwaite model is parameterised for an east Africa setting. We assumed that the clinical progression of HIV was similar in these populations. Table 1 summarises key features of the models. Our paper focuses on the implementation of these models for health-economic analysis; see the appendix for further details on the models themselves.
We applied country-specifi c unit costs to each of these models to generate analyses for three countries representative of higher-resource, mid-resource, and lower-resource settings within southern Africa: South Africa, Zambia, and Malawi, respectively (appendix).
Choice of alternative monitoring strategies
We evaluated four sets of monitoring strategies, including clinical monitoring alone, CD4 cell count alone, routine viral load monitoring alone, at various thresholds; and two strategies comprising combinations of monitoring approaches. We also used a hypothetical scenario of no monitoring and no switching as a baseline comparator to establish the incremental costs 
Costs and outcomes
We estimated costs from a health-sector perspective, in which only costs falling on the health system are included, and any wider, societal costs or benefi ts are not included. We projected health-care resource use in the models (number of clinic visits, number and type of monitoring tests, fi rst-line and second-line antiretroviral drugs prescribed, additional health-care use associated with disease progression) and applied associated unit costs representative of health-care delivery to estimate the total costs of strategies (all cost assumptions are listed in the appendix). Unit costs included personnel time, building costs, training, and facility management; we incorporated programmatic (above facility) costs on the basis of proportional mark-ups on unit costs of resource inputs. We summarised the health eff ects of the alternative strategies in the form of disability-adjusted life-years (DALYs) averted, a measure that captures the extent to which the interventions reduce the premature death and ill-health caused by a disease, including, in the HIV Synthesis model, reductions in morbidity and mortality from the prevention of onward HIV transmission.
5,6
DALYs averted for all scenarios run by each model are presented in the appendix. In our scenarios, 1 life-year in perfect health receives a weight of 0, whereas 1 life-year lived with a WHO stage 3 or 4 event (developed on the basis of viral load monitoring, CD4 cell count, and failure or absence of antiretroviral therapy) receives a substantial weight (0·547), and 1 life-year lived with asymptomatic HIV (eg, on successful antiretroviral therapy) receives a moderate weight of 0·053, portraying the decrement in the quality of life from these conditions. 12, 13 We estimated DALYs averted by applying DALY-weights to years lived and clinical events generated by the models, and not through estimating total burden of disease in the countries. Both costs and outcomes are discounted to 2012 present value in US dollars using a 3% discount rate.
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Economic analyses
The expected costs and health outcomes (DALYs averted) associated with each of the monitoring alternatives can be compared to inform which is likely to represent the best value from available resources. 14, 15 We ranked the strategies by eff ectiveness, removing those less eff ective and more costly than an alternative (ie, subject to dominance) or a linear combination of alternatives (subject to extended dominance). We compared all remaining strategies using incremental cost-eff ectiveness ratios (ICERs), showing the additional cost per unit of health gain (DALY averted) from a strategy compared with the next most eff ective alternative. ICERs are represented graphically in the form of cost-eff ectiveness frontiers that connect those strategies that provide the greatest health returns at any given cost. Importantly, ICERs alone cannot show which strategy is likely to be most appropriate for a particular setting: this requires comparison with a cost-eff ectiveness threshold.
The appropriate threshold in a particular setting depends on the opportunity costs of committing resources to fund an intervention, measured in terms of the health gains foregone because of displacement of alternative interventions that would not then be provided. An intervention can therefore only be deemed cost eff ective if the health gains that the intervention generates exceed what would have been gained if that intervention was not adopted and the resources were deployed elsewhere.
Opportunity costs themselves depend on the decision context and how else resources could be spent. In situations where scale-up of antiretroviral therapy is not complete, opportunity costs might include health gains from the provision of antiretroviral therapy using lowercost monitoring approaches to those in need who are not currently receiving treatment. We therefore compared patient monitoring results with estimates of the cost eff ectiveness of antiretroviral therapy to infer the valuefor-money of monitoring alternatives (ie, we compared the health benefi ts of money spent on monitoring with money spent on expanding antiretroviral therapy).
Sensitivity analyses investigate how results change with lower testing costs (as might be expected with the arrival of point-of-care or other new technologies) and reduced second-line antiretroviral drugs costs. These are presented in the form of incremental net monetary benefi t (I-NMB), of routine viral load monitoring compared with the best monitoring alternative at a particular cost-eff ectiveness threshold. I-NMB is a measure of the value of health gains, on a monetarised scale, resulting from an intervention compared with the health gains that could be realised if the resources required to fund that intervention were used for alternative purposes. 15 A positive I-NMB for routine viral load monitoring therefore indicates it is cost eff ective compared with other monitoring alternatives at a given cost-eff ectiveness threshold, whereas a negative I-NMB indicates the health gains are not large enough relative to costs to recommend its adoption.
Role of the funding source
WHO authors contributed to the design of the study, the selection of settings considered and strategies evaluated, but had no role in the development or selection of epidemiological models, the conduct of the analyses, or in ter pretation of results. The Bill & Melinda Gates Foundation had no role in the design of the analysis, interpretation of the results, or the decision to submit the manuscript for publication. The corresponding author had fi nal responsibility for the decision to submit for publication.
Results
The ICERs per DALY averted for each strategy are presented for Zambia in fi gure 1. Signifi cantly, the results from Malawi and South Africa were in precise qualitative agreement in that the ranking of each CD4-CA=clinical monitoring plus CD4 monitoring, switching at fall of CD4 cell count below baseline or of 50% or more from peak value on treatment. CD4/TGVL=targeted viral load strategy (viral load is used to confi rm a suspected failure based on immunological criteria). >500=switching at >500 copies per mL. >5K=switching at >5000 copies per mL. >10K=switching at >10 000 copies per mL. CD4<100/S4=switching at <100 cells per μL or new stage 4 event. *Dominated or extendedly dominated strategies. scenario along the cost frontier is the same across the three countries (appendix). All models show that no monitoring and no switching (ie, maintaining one line of antiretroviral therapy) is the least costly and least eff ective strategy in the base case analyses. Viral load monitoring every 6 months (VL6) is the most costly and most eff ective alternative in every model; viral load monitoring every 12 months (VL12, switching at >1000 copies per mL) is the nextmost-eff ective strategy in all models and is also slightly less costly.
Clinical and CD4-based monitoring approaches represent intermediate alternatives in cost and eff ectiveness in all models (fi gure 1). In the HIV Synthesis model, clinical monitoring (switching on a new WHO stage 3 or 4 event [CM S3/4]) off ers notable benefi ts at low incremental costs compared with no monitoring and no switching. The addition of CD4 monitoring (CD4-CA) to clinical monitoring alone confers a benefi t particularly in the HIV Synthesis and Braithwaite models, at an incremental cost meaning that it might be aff ordable in more settings than regular viral load monitoring. The Braithwaite results lend support to a targeted viral load strategy (CD4/TGVL, whereby a viral load is used to confi rm a suspected failure based on immunological criteria), which might be considered as a stepping stone towards the routine use of viral load monitoring-perhaps as programmes wait for cheaper point-of-care viral load monitoring to become widely available. This strategy would be less likely to be favoured, however, if it meant new viral load laboratory infrastructure had to be built or if it led to viral load machines being used at low volume and higher unit costs. Furthermore, we note that CD4-CA lies very close to the frontier in the Braithwaite model.
To assess whether improvements in patient monitoring should be prioritised over expanded coverage of antiretroviral therapy, we ran the Braithwaite model using costs from Malawi. We assumed that the antiretroviral therapy coverage (ie, the proportion of people eligible for antiretroviral therapy who are receiving it) was currently 50%, and that clinical monitoring was used for patients on antiretroviral therapy. In these respects, the model represents the situation in many eastern and southern African countries, where despite recommendations for CD4 or viral load monitoring being in place, scale-up of these strategies is limited and clinical monitoring remains widespread (median antiretroviral therapy coverage level noted in east and southern Africa is 56% 16 ). We considered a situation in which an HIV/AIDS programme has a choice between investing additional resources in routine 6-monthly viral load monitoring (while maintaining antiretroviral therapy coverage at 50%), or in increasing antiretroviral therapy coverage from 50% while still using clinical monitoring. In this hypothetical example, increasing antiretroviral therapy coverage-rather than upgrading patient monitoringwould be expected to generate much greater health benefi ts (fi gure 2). This result is consistent with the enormous benefi ts of antiretroviral therapy for patients with CD4 cell count of about 350 cells per μL compared with not receiving antiretroviral therapy at all, and the relatively modest benefi ts associated with the more extensive patient monitoring strategies in all the models (fi gure 1).
Other studies have also estimated that health gains for introducing antiretroviral therapy with clinical monitoring compared with no antiretroviral therapy can be realised at much lower ICERs than we estimate for the introduction of CD4 and viral load monitoring (Braithwaite, 2011 , estimates an ICER of $600 per quality-adjusted life-year [QALY] gained for two lines of antiretroviral therapy with clinical monitoring and no fi xed assumptions on the number of regimens available versus no antiretroviral therapy, which is similar to previous published estimates of $590 per life-year gained, 17 and $628 per QALY gained with one line of antiretroviral therapy only 18 ). In some other settings with high antiretroviral therapy coverage using CD4 monitoring, such as Zambia, the relevant policy choice would seem to be whether to spend additional resources on the provision of viral load monitoring or increasing the antiretroviral therapy eligibility criteria to CD4 cell count lower than 500 cells per μL. An additional analysis was run in the Braithwaite model to examine these alternatives (fi gure 3). The fi ndings suggest that earlier initiation of antiretroviral therapy, while still using CD4 monitoring, would cost less and generate greater health gains than would keeping the threshold of antiretroviral therapy initiation at 350 cells per μL and using viral load monitoring. This fi nding is also indicated in the low ICERs (less than $290 per DALY averted in Zambia) that have recently been reported for earlier antiretroviral therapy initiation in those already in care. 19 To assess the sensitivity of our results to particular cost assumptions, and to examine how results might change in response to changing costs, we constructed two alternative scenarios: (1) reduced costs of second-line antiretroviral regimens, with second-line costing the same as average current fi rst-line antiretroviral regimen costs; and (2) reduced costs of providing assays, which might be expected with the development of new CD4 cell count and viral load technologies, including point of care tests, of $4 per test for CD4 cell count and $10 per test for viral load monitoring (compared with the $9·50 per test for CD4 cell count and $45 per test for viral load monitoring used in the original analyses shown in fi gure 1). Figure 4 shows the I-NMB associated with routine 12-monthly viral load monitoring compared with the best non-routine viral load monitoring strategy. 14, 15 The I-NMB of routine viral load monitoring can be interpreted as the diff erence in the value of health gains generated from routine viral load monitoring and the value of health gains foregone as a result of those resources required to fund this monitoring strategy being unavailable to deliver other interventions, at particular cost-eff ectiveness threshold levels. At higher cost-eff ectiveness thresholds, resources buy fewer health gains elsewhere in the healthcare system and therefore the I-NMB of routine viral load monitoring increases. This might be the case, for instance, if a country has full antiretroviral therapy coverage and few other opportunities to generate health gains at low cost. However, at lower cost-eff ectiveness thresholds, the higher costs of routine viral load monitoring are of greater consequence because they displace investments in interventions that could off er health gains at low cost.
Reduced second-line costs and reduced testing costs would make 12-monthly viral load cost eff ective at lower cost-eff ectiveness thresholds than under base case assumptions (marked by where the lines cross the x-axis). However, the magnitude of these eff ects varies somewhat across the models. In the HIV Synthesis model, reduced second-line costs had very little eff ect on the cost eff ectiveness of routine viral load monitoring, but when the costs of the tests themselves fall, routine viral load monitoring becomes cost eff ective at a much lower threshold. In the Braithwaite and Estill models, reductions in the costs of second-line treatment were 
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Discussion
This analysis shows that a limited availability of resources to monitor patients should not be a barrier to scale-up of antiretroviral therapy. We fi nd that expanding treatment to more patients at existing thresholds for antiretroviral therapy initiation, or initiating antiretroviral therapy at higher CD4 cell counts while using clinical or immunological monitoring, would be a more eff ective use of resources than investing in more extensive patient monitoring using viral load tests. However, we also fi nd that viral load monitoring would confer additional benefi ts to patients and populations, especially over the long term, and that if the cost of viral load monitoring falls substantially, then it might become a cost-eff ective strategy in future, particularly in settings with high antiretroviral therapy coverage (panel). A major strength of this analysis is that it draws on various independent models, which come to very similar conclusions. This provides reassurance that the conclusions are robust to diff erent ways in which the disease progression and monitoring can be represented in models. Although we have not provided results for the models across ranges of assumptions for adherence, delays in switching patients, and other factors, we know of no data that suggest these issues would interfere with the overall conclusions we have drawn about the relative priorities of the diff erent strategies. We have not explicitly presented the impact of monitoring on HIV drug resistance or HIV transmission, but we emphasise that this is included in two of the models presented (table 1) and its eff ects are captured in the aggregate estimate of impact. Furthermore, it is possible that, by parameterising the models on the basis of trial data, the models overestimate the eff ect of monitoring compared with what would happen in real programmes. There is no reason to believe, however, that this would systematically bias our result to favouring one strategy over another, although there would be great benefi t in evaluating the performance of these alternative strategies in routine programmes to test this assumption.
The systematic nature of our compiled analysis has aff orded insights into the underlying reasons for the models to give slightly diff erent results in some cases. Particularly, in the HIV Synthesis model, CD4 monitoring strategies perform better relative to other strategies than is the case in the two other models. This diff erence seems to be because, in that model, the proportion of life-years lived with immunological failure where there is also virological failure (at >1000 copies per mL) is higher than in the Braithwaite model (and higher than the proportion of concurrent failures [as episodes, not life-years lived] in the Estill model). It is also higher than some reports in the literature of the positive predictive values of CD4 failure for virological failure, although these studies are based largely on people who initiated ART fairly recently, and the correlation between virological and immunological failure may increase with time on ART. [32] [33] [34] [35] [36] [37] [38] [39] Thus, in the HIV Synthesis model, the CD4 information is assumed to be a more reliable guide to viral failure than elsewhere, reducing the marginal gains in health from using viral load monitoring in that model.
Other published models besides the three used here have also examined optimal strategies for antiretroviral therapy monitoring, in a range of settings, and have fi ndings that are consistent with our results.
5,9,20 One model, however, stands in contrast: Hamers and colleagues 10 previously suggested that viral load monitoring would be cost-saving and could improve life-expectancy.
Panel: Research in context
Systematic Review
We searched PubMed, Medline, and Google Scholar for modelling studies published between Sept 15, 2007, and Sept 15, 2012 , with search terms "viral load monitoring", "patient monitoring", "cost-eff ectiveness", "mathematical modelling", "antiretroviral therapy", "modelling patient monitoring", and "HIV treatment monitoring." A list of studies reviewed (including some before Sept 15, 2007 ) is shown in the appendix. Patient monitoring models were last reviewed in 2010. 20 Mathematical models that have attempted to represent disease progression and monitoring are consistent with trial and observational data: immunological monitoring off ers some morbidity and mortality benefi t (ie, less time spent with clinical events, fewer deaths) over clinical monitoring, and virological monitoring might off er some morbidity and mortality benefi t over immunological monitoring. [4] [5] [6] [7] [8] 11 Two randomised controlled trials have found that routine CD4 monitoring reduces patient morbidity and mortality relative to clinical monitoring alone. [21] [22] [23] Several studies have evaluated the added eff ect of viral load monitoring compared with CD4 or clinical monitoring, but have not found major eff ects on morbidity or mortality. 21, 22, [24] [25] [26] [27] However, compared with CD4 monitoring 21, 24 or clinical monitoring, 26, 27 routine CD4 and viral load monitoring led to more patient switching to second-line drugs. Routine use of viral load was found to lead to more frequent switches to second-line drugs, compared with use of viral load only to confi rm a failure based on clinical or immunological criteria. 25 It has also been suggested that viral load monitoring (and by implication, targeted viral load for confi rmation of immunological failure) might prevent unnecessary switches to second-line therapy in patients who are failing clinically or immunologically but not virologically. 28 Less time spent with non-suppressed viral load could reduce the development of resistance 5, 28, 29 and the onward transmission of HIV;
5, 30, 31 however, Laurent and colleagues 26, 27 found no diff erence in the proportion of resistance in the clinical and laboratory arms, and Jourdain and colleagues 23 found just one case with resistance mutations in the CD4 arm.
Interpretation
Drawing overarching conclusions from existing patient monitoring models is complicated by models' use of diff erent cost inputs and heterogeneity in strategies modelled. Our analysis shows that three models brought together and run on a core set of scenarios with the same costs come to largely similar conclusions. It also confi rms that these modelling results are largely consistent with the trial literature, and over a longer timeframe than the trial data.
resources, the relatively modest anticipated benefi t of viral load monitoring is worth the added cost, and whether the opportunity costs in morbidity and mortality of forgoing the use of these resources for other eff orts is acceptable. We show here that routine viral load monitoring at current cost might be appropriate only in wealthier countries, especially those that have scaled-up to close-to-full antiretroviral therapy coverage, or if the cost of viral load testing were to fall considerably.
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TBH conceived the project and led the overall HIV Modelling Consortium Guidelines work. DK, PR, and TBH led the coordination of this work and wrote the fi rst draft of the report. PR led the cost modelling and cost-eff ectiveness analysis. RSB, AP, and NB were the principal authors contributing novel modelling and VC, JE, OK, LS, JK, and KN assisted with contributing modelling results. DK, PR, RSB, AP, NB, AB, SW, NM, VC, AC, JE, RG, AH, OK, LS, AW, and TBH all contributed to the design of the study, interpreting results and drafting the report. SW and NM provided guidance on costing, economic analysis of strategies and presentation of results. PE, MD, and GH contributed to articulating the research question. Programmes need to decide how to use available resources for the benefi t of the populations they serve. Unfortunately, not all health-care interventions that off er health gains can be funded, and adoption of interventions that require additional resources means that these resources are then unavailable for the delivery of other interventions that could also generate health gains. Decision makers therefore need to determine a value at which the costs per health gains associated with a more eff ective, but more expensive, intervention are deemed acceptable such that committing resources to that intervention is likely to improve population health. One threshold used by WHO is that any intervention that generates a unit of health gain (DALY averted) at less than three times gross domestic product (GDP) per capita of a country is "relatively cost eff ective" and anything less than GDP per capita "highly cost eff ective". 40 However, there is little evidence to support these thresholds and so instead we compare results to the health gains that could be achieved through committing resources to the expansion of antiretroviral therapy coverage. There might, however, be other opportunity costs both within the realm of HIV/ AIDS services (such as using diff erent drug regimens) as well as in other areas of the health system or even in other sectors entirely.
Confl icts of interest
These analyses are intended to contribute to deliberative processes of resource prioritisation. There are also likely to be other policy goals in addition to maximising health gains. A concern for equity, for example, could favour the adoption of a cheaper but less-eff ective monitoring strategy if its lower cost means that monitoring can be delivered to a greater number of people. 41 Specifi c practical considerations will also be important, such as existing laboratory infrastructure capabilities and the timing of procurement cycles. Furthermore, these decisions should be re-evaluated as antiretroviral therapy programmes expand and new diagnostics are developed or prices are reduced. The anticipated future availability of point-of-care technologies is likely to be particularly important, since those new tests might provide even greater benefi ts than our analysis of their potential lower cost implies, such as allowing more rapid generation and delivery of results in more remote communities. Also, in settings where coverage of antiretroviral therapy at high CD4 cell counts increases, viral load monitoring might enhance the impact that antiretroviral therapy has on reducing HIV transmission while the usefulness of current CD4 monitoring algorithms might be reduced.
The key question for programmes is not whether viral load monitoring provides benefi t to patients. Rather, the question is whether, given available programme
